このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Sutro Biopharma マネジメント
マネジメント 基準チェック /24
Sutro Biopharma'sの CEO はBill Newellで、 Jan2009年に任命され、 の在任期間は 15.42年です。 の年間総報酬は$ 2.13Mで、 32.2%給与と67.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は$ 1.08M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と5年です。
主要情報
Bill Newell
最高経営責任者
US$2.1m
報酬総額
| CEO給与比率 | 32.2% |
| CEO在任期間 | 15.7yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 1.6yrs |
| 取締役会の平均在任期間 | 5.3yrs |
経営陣の近況
Recent updates
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
報酬と市場: Billの 総報酬 ($USD 2.13M ) は、 US市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。
報酬と収益: Billの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Bill Newell (66 yo)
15.7yrs
在職期間
US$2,129,980
報酬
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 15.7yrs | US$2.13m | 0.41% $ 1.2m | |
| Chief Scientific Officer | less than a year | US$1.63m | 0.029% $ 83.9k | |
| Chief Medical Officer | 1.6yrs | US$2.34m | 0.030% $ 84.8k | |
| President & COO | less than a year | US$1.43m | 0.066% $ 188.8k | |
| Founder | no data | データなし | データなし | |
| CFO & Secretary | 11.7yrs | US$2.08m | 0.13% $ 371.5k | |
| Chief Technical Operations Officer | 1.3yrs | データなし | 0.039% $ 110.4k | |
| General Counsel | 3.5yrs | データなし | データなし | |
| Chief People & Communications Officer | 16.7yrs | US$1.30m | 0.10% $ 290.0k | |
| Chief Business Development Officer | less than a year | データなし | データなし | |
| Vice President & Controller | no data | データなし | データなし |
1.6yrs
平均在職期間
62yo
平均年齢
経験豊富な経営陣: STROの経営陣は 経験豊富 とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 15.7yrs | US$2.13m | 0.41% $ 1.2m | |
| Independent Chair of the Board | 5.3yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.6yrs | US$138.11k | 0.069% $ 196.0k | |
| Independent Director | 15.1yrs | US$140.11k | 0.027% $ 78.2k | |
| Member of Scientific Advisory Board | 1.7yrs | US$1.53m | 0.12% $ 349.3k | |
| Chair of the Scientific Advisory Board | 4.3yrs | データなし | データなし | |
| Independent Director | 6.2yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of the Clinical Advisory Board | 4.3yrs | データなし | データなし | |
| Independent Director | 2.8yrs | US$150.28k | 0% $ 0 |
5.3yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: STROの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。